• main

PharmNovo combines smart chemistry and bioscience to discover new medicines to treat diseases of the nervous system
PharmNovo blends academic and industrial expertise to bring safe and effective medicines to the marketplace
Development of novel receptor agonists and antagonists to treat chronic pain and related CNS disorders
Feel free to Contact us
9 October, 2016

PharmNovo give a PN6047 pitch at the French-Swedish Life Science Day, held 20 October at the Swedish Embasy in Paris

Read more
25 September, 2016

Over the last year the company has started to attract investors to the PharmNovo portfolio in chronic pain. This is now intensifying as our first product will move to GLP regulatory toxicology in 2017 and first in man studies are planned in 2018.

Read more